Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

1. A method of treating acute or delayed cardiotoxic events in a subject treated with a chemotherapeutic agent, the method comprising: administering to the subject having or at risk of the cardiotoxic event a therapeutically effective amount of a 15-PGDH inhibitor, wherein the chemotherapeutic induces cardiomyopathy and/or a reduction of cardiac ejection fraction in the subject and is selected from doxorubicin, epirubicin, daunorubicin, idarubicin, valrubicin, pirarubicin, amrubicin, aclarubicin, zorubicin, an anti-ErB2 antibody, and an anti-HER2 antibody; and wherein the 15-PGDH inhibitor has the following formula (V):

or a pharmaceutically acceptable salt thereof,

wherein n is 0-2

X 6 is independently is N or CR c

R 1 , R 6 , R 7 , and R c are each independently hydrogen or a substituted or unsubstituted group selected from: C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, —Si(C 1 -C 3 alkyl) 3 , hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carboxylato, carbamoyl, C 1 -C 24 alkyl-carbamoyl, arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, C 1 -C 24 alkyl amino, C 5 -C 20 aryl amino, C 2 -C 24 alkylamido, C 6 -C 20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C 1 -C 24 alkylsulfanyl, arylsulfanyl, C 1 -C 24 alkylsulfinyl, C 5 -C 20 arylsulfinyl, C 1 -C 24 alkylsulfonyl, C 5 -C 20 arylsulfonyl, sulfonamide, phosphono, phosphonato, phosphinato, phospho, phosphino, polyalkylethers, phosphates, and phosphate esters, and combinations thereof, and wherein R 6 and R 7 is optionally linked to form a cyclic or polycyclic ring, wherein the ring is a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, and a substituted or unsubstituted heterocyclyl; and

U 1 is N, C—R 2 , or C—NR 3 R 4 , wherein R 2 is selected from the group consisting of a H, a lower alkyl group, O, (CH 2 ) n1 OR′ (wherein n1=1, 2, or 3), CF 3 , CH 2 —CH 2 X, O—CH 2 —CH 2 X, CH 2 —CH 2 —CH 2 X, O—CH 2 —CH 2 X, X, (wherein X═H, F, Cl, Br, or I), CN, (C═O)—R′, (C═O)N(R′) 2 , O(CO)R′, COOR′ (wherein R′ is H or a lower alkyl group), and wherein R 1 and R 2 may be linked to form a cyclic or polycyclic ring, wherein R 3 and R 4 are the same or different and are each selected from the group consisting of H, a lower alkyl group, O, (CH 2 ) n1 OR′ (wherein n1=1, 2, or 3), CF 3 , CH 2 —CH 2 X, CH 2 —CH 2 —CH 2 X, (wherein X═H, F, Cl, Br, or I), CN, (C═O)—R′, (C═O)N(R′) 2 , COOR′ (wherein R′ is H or a lower alkyl group), and R 3 or R 4 may be absent.

2. The method of claim 1 , wherein the 15-PGDH inhibitor has the following formula (VI):

or a pharmaceutically acceptable salt thereof,

wherein n=0-2;

X 6 is N or CR c ;

R 1 is selected from the group consisting of branched or linear alkyl and,

wherein n 2 =0-6 and X is any of the following: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 , CN, N(R 73 ) 2 ,

(n 3 =0-5, m=1-5), and

n 4 =0-5);

R 5 is selected from the group consisting of H, Cl, F, NH 2 , and N(R 76 ) 2 ;

R 6 and R 7 can each independently be one of the following:

each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72 , R 73 , R 74 , R 76 , and R c are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, —Si(C 1 -C 3 alkyl) 3 , hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carboxylato, carbamoyl, C 1 -C 24 alkyl-carbamoyl, arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, C 1 -C 24 alkyl amino, C 2 -C 24 alkyl amino substituted with hydroxyl, C 5 -C 20 aryl amino, C 2 -C 24 alkylamido, C 6 -C 20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C 1 -C 24 alkylsulfanyl, arylsulfanyl, C 1 -C 24 alkylsulfinyl, C 5 -C 20 arylsulfinyl, C 1 -C 24 alkylsulfonyl, C 5 -C 20 arylsulfonyl, sulfonamide, phosphono, phosphonato, phosphinato, phospho, phosphino, polyalkylethers, phosphates, phosphate esters and combinations thereof.

3. The method of claim 1 , wherein the 15-PGDH inhibitor has the following formula following formula:

or pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the amount of 15-PGDH inhibitor administered to the subject is an amount effective to enhance the ejection fraction or mitigate reduction of the ejection fraction of the subject treated with the chemotherapeutic.

5. The method of claim 1 , wherein the amount of 15-PGDH inhibitor administered to the subject is an amount effective to reduce the level atrial natriuretic factor in the subject.

6. The method of claim 1 , wherein the amount of 15-PGDH administered to the subject is an amount effective to reduce chemotherapeutic induced cardiac fibrosis in the subject.

7. The method of claim 1 , wherein the 15-PGDH inhibitor is administered to the subject orally.